Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.8400 (2.67%) ($3.8400 - $3.8400) on Wed. Mar. 9, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.03% (three month average) | RSI | 32 | Latest Price | $3.8400(2.67%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.3% a day on average for past five trading days. | Weekly Trend | AUTL declines -7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(65%) IBB(61%) IBUY(53%) IWO(51%) XRT(49%) | Factors Impacting AUTL price | AUTL will decline at least -2.015% in a week (0% probabilities). VIXM(-49%) SHY(-30%) TLT(-29%) VXX(-27%) TIP(-26%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.015% (StdDev 4.03%) | Hourly BBV | 0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-13.82(-459.9%) | Resistance Level | $4.04 | 5 Day Moving Average | $3.65(5.21%) | 10 Day Moving Average | $3.74(2.67%) | 20 Day Moving Average | $4.04(-4.95%) | To recent high | -44.1% | To recent low | 9.6% | Market Cap | $201m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |